ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

September 7, 2022 GMT

HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will be participating in the following upcoming investor conferences.

2022 Wells Fargo Healthcare Conference
Date: Thursday, September 8, 2022
Format: 1x1 Meetings only
Location: Boston, MA

Morgan Stanley 20th Annual Global Healthcare Conference
Date: Monday, September 12, 2022
Format: 1x1 Meetings only
Location: New York, NY

Cantor Oncology, Hematology & HemeOnc Conference
Date: Wednesday, September 28, 2022
Format: Panel Presentation and 1x1 Meetings
Panel: Cell Therapy in Solid Tumors
Location: New York, NY

About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has a clinical and strategic collaboration with the National Cancer Institute. For more information, please visit www.alaunos.com.

ADVERTISEMENT

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
alex.lobo@sternir.com